BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33361404)

  • 21. Global PD-L1 Signals and Tumor-Infiltrating Lymphocytes: Markers of Immunogenicity in Different Subsets of Merkel Cell Carcinoma and Potential Therapeutic Implications.
    Walsh NM; Castonguay MC; Carter MD; Pasternak S; Ly TY; Doucette S; Hanly JG; Saggini A; Cerroni L
    Am J Dermatopathol; 2019 Nov; 41(11):819-825. PubMed ID: 31634167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
    Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
    Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 in circulating exosomes of Merkel cell carcinoma.
    Zanella A; Vautrot V; Aubin F; Avoscan L; Samimi M; Garrido C; Gobbo J; Nardin C
    Exp Dermatol; 2022 Jun; 31(6):869-877. PubMed ID: 34994009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases.
    Ren Y; Lv Q; Yue W; Liu B; Zou Z
    Melanoma Res; 2020 Feb; 30(1):85-101. PubMed ID: 31095042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
    Yu H; Chen Z; Ballman KV; Watson MA; Govindan R; Lanc I; Beer DG; Bueno R; Chirieac LR; Chui MH; Chen G; Franklin WA; Gandara DR; Genova C; Brovsky KA; Joshi MM; Merrick DT; Richards WG; Rivard CJ; Harpole DH; Tsao MS; van Bokhoven A; Shepherd FA; Hirsch FR
    J Thorac Oncol; 2019 Jan; 14(1):25-36. PubMed ID: 30253973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.
    Manson QF; Schrijver WAME; Ter Hoeve ND; Moelans CB; van Diest PJ
    Clin Exp Metastasis; 2019 Feb; 36(1):29-37. PubMed ID: 30547271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.
    Schneider S; Kadletz L; Wiebringhaus R; Kenner L; Selzer E; Füreder T; Rajky O; Berghoff AS; Preusser M; Heiduschka G
    Histopathology; 2018 Oct; 73(4):573-584. PubMed ID: 29742291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of the expression of FOXP3 and TIGIT in Merkel cell carcinoma.
    Iwasaki T; Hayashi K; Matsushita M; Nonaka D; Matsumoto T; Taniguchi M; Kuwamoto S; Umekita Y; Oda Y
    Sci Rep; 2023 Aug; 13(1):13114. PubMed ID: 37573372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma.
    Buderath P; Mairinger F; Mairinger E; Böhm K; Mach P; Schmid KW; Kimmig R; Kasimir-Bauer S; Bankfalvi A; Westerwick D; Hager T
    Int J Gynecol Cancer; 2019 Nov; 29(9):1389-1395. PubMed ID: 31492714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma.
    Spassova I; Ugurel S; Kubat L; Zimmer L; Terheyden P; Mohr A; Björn Andtback H; Villabona L; Leiter U; Eigentler T; Loquai C; Hassel JC; Gambichler T; Haferkamp S; Mohr P; Pfoehler C; Heinzerling L; Gutzmer R; Utikal JS; Horny K; Schildhaus HU; Habermann D; Hoffmann D; Schadendorf D; Becker JC
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Merkel cell carcinoma: mitoses, expression of Ki-67 and bcl-2 correlate with disease progression.
    Vujic I; Marker M; Posch C; Mühlehner D; Monshi B; Breier F; Steiner A; Ortiz-Urda S; Rappersberger K
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):542-8. PubMed ID: 25088273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tropomyosin Receptor Kinase A Expression on Merkel Cell Carcinoma Cells.
    Wehkamp U; Stern S; Krüger S; Hauschild A; Röcken C; Egberts F
    JAMA Dermatol; 2017 Nov; 153(11):1166-1169. PubMed ID: 28793172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical study of apoptosis markers and involvement of chemokine CXCR4 in skin Merkel cell carcinoma.
    Tucci MG; Lucarini G; Giangiacomi M; Zizzi A; Criante P; Ricotti G; Biagini G
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1220-5. PubMed ID: 17062035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling.
    Martins C; Rasbach E; Heppt MV; Singh P; Kulcsar Z; Holzgruber J; Chakraborty A; Mucciarone K; Kleffel S; Brandenburg A; Hoetzenecker W; Rahbari NN; DeCaprio JA; Thakuria M; Murphy GF; Ramsey MR; Posch C; Barthel SR; Schatton T
    Sci Adv; 2024 Jan; 10(3):eadi2012. PubMed ID: 38241371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic relevance of high atonal homolog-1 expression in Merkel cell carcinoma.
    Gambichler T; Mohtezebsade S; Wieland U; Silling S; Höh AK; Dreißigacker M; Schaller J; Schulze HJ; Oellig F; Kreuter A; Stockfleth E; Stücker M; Bechara FG; Becker JC
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):43-49. PubMed ID: 27624714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Impact of MCPyV and TIL Subtyping in Merkel Cell Carcinoma: Evidence from a Large European Cohort of 95 Patients.
    Ricci C; Righi A; Ambrosi F; Gibertoni D; Maletta F; Uccella S; Sessa F; Asioli S; Pellilli M; Maragliano R; La Rosa S; Papotti MG; Asioli S
    Endocr Pathol; 2020 Mar; 31(1):21-32. PubMed ID: 31808008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Merkel Cell Carcinoma Therapeutic Update.
    Cassler NM; Merrill D; Bichakjian CK; Brownell I
    Curr Treat Options Oncol; 2016 Jul; 17(7):36. PubMed ID: 27262710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma.
    Hanna GJ; Kacew AJ; Tanguturi AR; Grote HJ; Vergara V; Brunkhorst B; Rabinowits G; Thakuria M; LeBoeuf NR; Ihling C; DeCaprio JA; Lorch JH
    Front Med (Lausanne); 2020; 7():198. PubMed ID: 32582722
    [No Abstract]   [Full Text] [Related]  

  • 39. B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density.
    Aung PP; Parra ER; Barua S; Sui D; Ning J; Mino B; Ledesma DA; Curry JL; Nagarajan P; Torres-Cabala CA; Efstathiou E; Hoang AG; Wong MK; Wargo JA; Lazar AJ; Rao A; Prieto VG; Wistuba I; Tetzlaff MT
    Clin Cancer Res; 2019 Jun; 25(11):3455-3467. PubMed ID: 30808776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.